Oral Akynzeo vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

  • STATUS
    Recruiting
  • End date
    Aug 31, 2023
  • participants needed
    530
  • sponsor
    Helsinn Healthcare SA
Updated on 25 September 2021

Summary

MyRisk: Efficacy and safety evaluation of oral Akynzeo in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.

Antiemetic guidelines recommendations are based on the emetogenic potential of the chemotherapy. Chemotherapy (CT) agents are divided in Highly, Moderately, Low and Minimally Emetogenic potential.

In addition to type of chemotherapy, several patient-related risk factors can increase the risk of CINV (chemotherapy-induced nausea and vomiting). Currently, there is limited consensus surrounding the most relevant patient risk factors that may predict the risk of CINV. Based on a recent study by Dranitsaris et al. (Dranitsaris et al. Ann Oncol. 2017 Jun 1; 28(6):1260-1267.), eight (8) predictive factors have been identified and an algorithm has been developed to incorporate these factors into the optimal selection of prophylactic

antiemetics
  1. nausea and/or vomiting in the prior cycle of chemotherapy
  2. use of non-prescribed antiemetics at home in the prior cycle of chemotherapy
  3. platinum or anthracycline-based chemotherapy
  4. age < 60 years
  5. expectations for (anticipating) nausea and/or vomiting
  6. <7 h of sleep the night before chemotherapy
  7. history of morning sickness during previous pregnancy
  8. cycle of chemotherapy (A negative association between risk and number of cycles was identified where the hazard for CINV was highest in cycles 1 and 2, with a gradual decline and plateau from cycle 3 onward).

The clinical application of this prediction tool has the potential to be an important resource for clinicians and may help to enhance patient care by optimizing the use of the antiemetics in a proactive manner.

Description

Antiemetic guideline recommendations are based on the emetogenic potential of chemotherapy and involve 4 levels of classification of intravenous chemotherapy agents, i.e., high, moderate, low and minimal; these have been accepted by major organisations. Moderate emetogenic chemotherapy (MEC) results in acute vomiting in 30% to 90% of cancer patients in the absence of antiemetic therapy. In addition to the chemotherapy type, several patient-related risk factors and clinical characteristics can increase CINV risk. These can include use of antiemetics inconsistent with international guidelines, younger age, prechemotherapy nausea, no complete CINV response in an earlier cycle, history of nausea/vomiting, (trait) anxiety, fatigue experience, and expectations of nausea/vomiting. Other studies have largely confirmed some of the key risk factors for CINV (history of vomiting during pregnancy, history of motion sickness, age, gender) and added other factors such as (chronic) alcohol consumption, body surface area, fewer hours slept the night prior to infusion, or advanced stage cancer. Currently, there is a limited consensus surrounding the most relevant patient risk factors that may predict CINV risk. Based on a recent study by Dranitsaris et al. eight predictive factors have been identified, and an algorithm has been developed to combine these patient-related risk factors into the optimal treatment of prophylactic antiemetics. These include:

  1. nausea and/or vomiting in the prior cycle of chemotherapy
  2. use of non-prescribed antiemetics at home in the prior cycle of chemotherapy
  3. platinum or anthracycline-based chemotherapy
  4. age < 60 years
  5. expectations for (anticipating) nausea and/or vomiting
  6. <7 h of sleep the night before chemotherapy
  7. history of morning sickness during previous pregnancy
  8. cycle of chemotherapy (A negative association between risk and number of cycles was identified where the hazard for CINV was highest in cycles 1 and 2, with a gradual decline and plateau from cycle 3 onward).

Akynzeo, an oral combination of the neurokinin 1 receptor antagonists (NK1 RA), netupitant and the 5-hydroxytryptamine (HT3) receptor antagonists (5-HT3 RA), palonosetron, is recommended by guidelines for the prevention of CINV. Akynzeo has been evaluated in a multicentre, randomised, double-blind, double-dummy phase II clinical trial at various dose ranges among 694 cisplatin-treated cancer patients from 44 sites (two countries); each NEPA (netupitant-palonosetron) dose significantly improves CINV prevention in cancer patients. Similar results were obtained in another international, randomised, double-blind and parallel group phase III clinical trial; NEPA prevented CINV in patients receiving MEC.

The current study primarily aimed to evaluate whether Akynzeo leads to a higher response rate compared with standard care in MEC regimen-treated patients who are identified to be at high risk based on the algorithm.

Details
Condition Chemotherapy-induced Nausea and Vomiting
Treatment NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose
Clinical Study IdentifierNCT04817189
SponsorHelsinn Healthcare SA
Last Modified on25 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Adult patients aged 18 years
Patients with a risk score of 13 as calculated by the algorithm - see [3.6.3.1](telnet://3.6.3.1). Baseline/screening: VISIT 0
Signed Informed consent
Both sexes
Patients with diagnosis of any cancer scheduled and intended to be treated for three consecutive cycles with a single dose of any IV MEC regimen, per cycle, including adjuvant or neo-adjuvant chemotherapy
Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Use of Standard of Care defined as a 5-HT3 RA + Dexamethasone (or equivalent corticosteroid) based-regimen on day 1 of chemotherapy for CINV prevention
Nave and non- nave to chemotherapy
The enrolled women should be a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test done by health care team within 1-24 hours before dosing the antiemetic treatment in both arms and outcome recorded in the medical records
Able to comply with study requirements

Exclusion Criteria

Patients receiving highly emetogenic chemotherapy (including anthracycline+cyclophosphamide-based chemotherapy)
Patients receiving oral moderately emetogenic chemotherapy drugs
Patients receiving opioids within 2 weeks prior to trial enrollment (longer use allowed)
Use of olanzapine as prophylaxis of CINV
Patients scheduled to receive radiotherapy concurrently with chemotherapy
Any illness or condition that, in the opinion of the physician, may confound the results of the study or pose unwarranted risks in administering the investigational product to the patient
Patients with mechanical risk factors for nausea (i.e. intestinal obstruction)
Patients with liver disease (as nausea is a common presenting symptom)
Patients with metabolic risk factors for nausea (i.e. electrolyte imbalances causing nausea/vomiting)
Chronic treatment with steroids (with the exception of inhaled or topical steroids)
Pregnancy and/or breast-feeding women
Women of childbearing potential refusing to use effective contraception during the whole study treatment and up to one month after study treatment with Akynzeo
Use of Standard of Care including an NK-1 RA-based regimen to prevent CINV
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note